What is the mechanism of action of Vemurafenib?

Vemurafenib is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma in whom the BRAF V600E mutation has been detected in an FDAapproved test. Vemurafenibis suitable for the treatment of patients with Erdheim-Chester disease who have BRAF V600 mutations. Vemurafenibis not indicated for the treatment of wild-type BRAFmelanoma.

Vemurafenibis a low molecular weight, oral BRAFserine-threonine kinase (including BRAF V600E) mutant form. Vemurafenib also inhibits other in vitro kinases at similar concentrations, such as CRAF, ARAF, wild-type BRAF, SRMS, ACK1, MAP4K5 and FGR. Some mutations in the BRAF gene, including V600E, result in constitutively activated BRAF proteins that can cause cell proliferation in the absence of growth factors required for normal proliferation. Vemurafenibhas anti-tumor effects in BRAF V600E mutated melanoma cells and animal models.

Vemurafenib is the first molecularly targeted therapy approved in the United States and Europe for the treatment of advanced melanoma. Its mechanism of action includes selective inhibition of mutated BRAF V600Ekinase, resulting in reduced signaling in the abnormal mitogen-activated protein kinase (MAPK) pathway. Vemurafenib is an oral tablet. Usually take it twice a day, once in the morning and once in the evening, with an interval of about 12 hours, with or without food. Take vemurafenib at approximately the same time each day. Follow the directions on your prescription label carefully and ask your doctor to explain any parts you don't understand. Take vemurafenib exactly as directed. Do not take more or less than prescribed by your doctor. Do not stop taking without consulting your doctorVemurafenib. The Turkish version of the original medicine costs more than 1,000 per box2. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.